TW202535473A - 用於增進癌症化學療效之組合物、營養補充劑及其用途 - Google Patents

用於增進癌症化學療效之組合物、營養補充劑及其用途

Info

Publication number
TW202535473A
TW202535473A TW114100270A TW114100270A TW202535473A TW 202535473 A TW202535473 A TW 202535473A TW 114100270 A TW114100270 A TW 114100270A TW 114100270 A TW114100270 A TW 114100270A TW 202535473 A TW202535473 A TW 202535473A
Authority
TW
Taiwan
Prior art keywords
selenium
fish oil
chemotherapy
cancer
cells
Prior art date
Application number
TW114100270A
Other languages
English (en)
Chinese (zh)
Inventor
滉 夏
Original Assignee
滉 夏
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 滉 夏 filed Critical 滉 夏
Publication of TW202535473A publication Critical patent/TW202535473A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/60Fish, e.g. seahorses; Fish eggs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
TW114100270A 2017-06-13 2018-06-13 用於增進癌症化學療效之組合物、營養補充劑及其用途 TW202535473A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762519093P 2017-06-13 2017-06-13
US201762519096P 2017-06-13 2017-06-13
US62/519,093 2017-06-13
US62/519,096 2017-06-13
US201762595002P 2017-12-05 2017-12-05
US62/595,002 2017-12-05
US201862670275P 2018-05-11 2018-05-11
US62/670,275 2018-05-11

Publications (1)

Publication Number Publication Date
TW202535473A true TW202535473A (zh) 2025-09-16

Family

ID=64658652

Family Applications (2)

Application Number Title Priority Date Filing Date
TW114100270A TW202535473A (zh) 2017-06-13 2018-06-13 用於增進癌症化學療效之組合物、營養補充劑及其用途
TW107120419A TW201906633A (zh) 2017-06-13 2018-06-13 用於增進癌症化學療效之組合物及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW107120419A TW201906633A (zh) 2017-06-13 2018-06-13 用於增進癌症化學療效之組合物及方法

Country Status (9)

Country Link
US (2) US10905725B2 (https=)
EP (1) EP3638247A4 (https=)
JP (3) JP7788129B2 (https=)
KR (2) KR20240171182A (https=)
CN (1) CN111556754A (https=)
CA (1) CA3066713A1 (https=)
IL (1) IL271328A (https=)
TW (2) TW202535473A (https=)
WO (1) WO2018231943A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL265786B (en) 2016-10-03 2022-09-01 Houn Simon Hsia Materials and methods for increasing radiotherapy against cancer
EP3638269B1 (en) 2017-06-13 2025-12-17 Houn Simon Hsia Nutritional supplement for enhancing cancer radiotherapy
US10905725B2 (en) * 2017-06-13 2021-02-02 Houn Simon Hsia Compositions and methods for enhancing cancer chemotherapy
US12029765B2 (en) 2017-06-13 2024-07-09 Houn Simon Hsia Compositions and methods for treating cancer
IL271327B2 (en) 2017-06-13 2024-11-01 Simon Hsia Houn Compositions for increasing tumor sensitivity to hyperthermia therapy
US20220175850A1 (en) * 2019-04-01 2022-06-09 Houn Simon Hsia Compositions and methods for cancer therapy
AU2021324673B2 (en) * 2020-08-10 2025-07-24 Houn Simon Hsia Compositions and methods for treating viral infection

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348483A (en) 1981-01-23 1982-09-07 Universal Foods Corporation Method for the production of chromium yeast
US4569836A (en) 1981-08-27 1986-02-11 Gordon Robert T Cancer treatment by intracellular hyperthermia
CA2010511A1 (en) 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
NZ248605A (en) 1993-05-28 1994-12-22 Abbott Lab Enteral nutritional product comprising protein and fat
US20020010144A1 (en) 1994-04-29 2002-01-24 Robert Sobol Enhancing the sensitivity of tumor cells to therapies
US5976548A (en) 1994-11-08 1999-11-02 Viva America Marketing, Inc. Nutritional supplement composition and use
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US6440464B1 (en) 1996-06-10 2002-08-27 Viva Life Science Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates
US6197295B1 (en) * 1996-09-25 2001-03-06 Viva America Marketing Corporation Dietary supplementation with, and methods for administration of yeast-derived selenium product
US5810888A (en) 1997-06-26 1998-09-22 Massachusetts Institute Of Technology Thermodynamic adaptive phased array system for activating thermosensitive liposomes in targeted drug delivery
CA2339473A1 (en) 1998-08-04 2000-02-17 John V. Kosbab Nutrient and therapeutic compositions for the treatment of cancer
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
US20050080468A1 (en) 2001-03-26 2005-04-14 Lawrence C. Christman Methods and apparatus for treating diseased tissue
EP1438971A4 (en) 2001-10-25 2005-01-12 Ttc Co Ltd IMMUNE AMPLIFIERS IN THERAPEUTIC THERAPY IN CANCER
NZ533737A (en) 2002-01-11 2006-02-24 Matthias Rath A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
US20040087490A1 (en) 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
AU2002951833A0 (en) 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
US7744930B2 (en) 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
US8663679B2 (en) 2004-04-29 2014-03-04 Abbott Laboratories Compositions for improving breast health in women
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US20060088574A1 (en) 2004-10-25 2006-04-27 Manning Paul B Nutritional supplements
US20070116802A1 (en) 2005-11-23 2007-05-24 Carl Germano High quality caloric composition
US8017147B2 (en) 2008-04-07 2011-09-13 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
US20090110674A1 (en) 2007-10-24 2009-04-30 Loizou Nicos C Health supplement
WO2009157759A1 (en) 2008-06-23 2009-12-30 N.V. Nutricia Nutritional composition for improving the mammalian immune system
EP3011843A1 (en) 2008-09-19 2016-04-27 Nestec S.A. Nutritional support of the immune system during anti-cancer treatment
US8257694B2 (en) 2009-05-14 2012-09-04 Product Partners, Llc Nutritional compositions for reducing oxidative damage
KR20120065276A (ko) 2009-05-29 2012-06-20 뉴 챕터, 인코포레이티드. 지질 조성을 조정하기 위한 조성물 및 방법
KR101275724B1 (ko) 2009-12-09 2013-06-17 한국전자통신연구원 단일 기판 집적 회로 장치 및 그 제조 방법
WO2011094579A2 (en) 2010-01-29 2011-08-04 New Chapter Inc. Mushroom compositions and methods for making and using
JP5882889B2 (ja) * 2010-03-15 2016-03-09 国立大学法人 岡山大学 抗腫瘍剤
US20120010688A1 (en) 2010-07-09 2012-01-12 Lamb Karl J Implantable conductive element and method of use inhyperthermic treatment
US9669053B2 (en) 2010-07-26 2017-06-06 Chemotherapeutics, Llc Compositions and methods for enhancing the effectiveness of systemic, HIPEC, IP, and related cancer treatments
WO2012122295A2 (en) 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin
WO2014054884A1 (ko) 2012-10-05 2014-04-10 연세대학교 산학협력단 민감화 물질을 포함하는 온열 치료용 조성물
US9072768B2 (en) 2013-01-22 2015-07-07 Kibow Biotech, Inc. Composition and method for increasing effectiveness of radiation or chemotherapy
US9107947B2 (en) 2013-01-31 2015-08-18 The Penn State Research Foundation Anti-cancer compositions and methods
WO2014159851A2 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Novel low density lipoprotein nanocarriers for targeted delevery of omega-3 polyunsaturated fatty acids to cancer
US20140294795A1 (en) * 2013-03-28 2014-10-02 Houn Simon Hsia Nutritional Composition
MX370055B (es) 2013-04-22 2019-11-29 Smartfish As Uso de una composición que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cáncer.
SG11201600657RA (en) 2013-07-31 2016-02-26 Meiji Co Ltd Nutritional composition for inhibiting growth of tumor
EP3033091B1 (en) 2013-08-16 2022-09-07 Versitech Limited Probiotic composition and use thereof in the prevention and treatment of hepatocellular carcinoma
US20170246136A1 (en) 2014-09-24 2017-08-31 OliVentures, Inc. Pharmaceutical product, medical food or dietary supplement for preventing cancer and inflammatory diseases
CN105641000A (zh) 2015-06-01 2016-06-08 深圳市康道生物有限公司 一种含灰树花提取物的抗肿瘤组合物及其制备方法
JP7411327B2 (ja) 2015-11-18 2024-01-11 サイバーグ・コンサルティング・リミテッド・ライアビリティ・カンパニー 天然抽出物を含有する組成物、ならびに皮膚および毛髪に対するその使用
CN105617358A (zh) 2015-12-29 2016-06-01 广州市戴菊科技发展有限公司 一种具有抗肿瘤功能的医用食品及其制备方法
JP6376186B2 (ja) 2016-08-04 2018-08-22 トヨタ自動車株式会社 サスペンションメンバ
IL265786B (en) 2016-10-03 2022-09-01 Houn Simon Hsia Materials and methods for increasing radiotherapy against cancer
CN106822560A (zh) 2017-04-07 2017-06-13 湖北工程学院 药物组合物及其制备方法
US10905725B2 (en) * 2017-06-13 2021-02-02 Houn Simon Hsia Compositions and methods for enhancing cancer chemotherapy
EP3638269B1 (en) 2017-06-13 2025-12-17 Houn Simon Hsia Nutritional supplement for enhancing cancer radiotherapy

Also Published As

Publication number Publication date
EP3638247A2 (en) 2020-04-22
IL271328A (en) 2020-01-30
US10905725B2 (en) 2021-02-02
CN111556754A (zh) 2020-08-18
KR20240171182A (ko) 2024-12-06
JP7788129B2 (ja) 2025-12-18
TW201906633A (zh) 2019-02-16
KR20200079229A (ko) 2020-07-02
WO2018231943A2 (en) 2018-12-20
CA3066713A1 (en) 2018-12-20
US20190134102A1 (en) 2019-05-09
US12036246B2 (en) 2024-07-16
EP3638247A4 (en) 2021-03-03
JP2026026381A (ja) 2026-02-16
JP2023115357A (ja) 2023-08-18
KR102736425B1 (ko) 2024-11-28
US20210252076A1 (en) 2021-08-19
WO2018231943A3 (en) 2019-02-28
JP2020523370A (ja) 2020-08-06

Similar Documents

Publication Publication Date Title
JP7465313B2 (ja) がん放射線療法を増強するための組成物および方法
TW202535473A (zh) 用於增進癌症化學療效之組合物、營養補充劑及其用途
Fujiki et al. Green tea: An effective synergist with anticancer drugs for tertiary cancer prevention
US11541079B2 (en) Compositions and methods for enhancing cancer immunotherapy
US11433105B2 (en) Compositions and methods for enhancing hyperthermia therapy
Diorio et al. Nutritional traditional and complementary medicine strategies in pediatric cancer: A narrative review
Cocetta et al. Clinical evidence of interaction between nutraceutical supplementation and platinum-based chemotherapy
EP4061398B1 (fr) Extrait liquide aqueux de spiruline pour la prévention et/ou le traitement des neuropathies périphériques chimio-induites et leurs symptômes, composition et utilisation correspondantes
TW202102236A (zh) 用於癌症免疫治療的組成物及方法
US20240350558A1 (en) Compositions and Methods for Treating Inflammation
US20240358769A1 (en) Compositions and Methods for Treating Inflammation Associated with IL-6
HK40030492A (en) Compositions and methods for enhancing cancer chemotherapy
Patil et al. Importance of Diet and Other Nutrients for the Management of Migraine Pain
Ernst Alternative Cancer Cures
CN119138535A (zh) 基于Xu5P提高剂的肿瘤抑制益生菌功能饮料及其制备方法
CA3191162A1 (en) Compositions and methods for treating viral infection
HK40011860A (en) Compositions and methods for enhancing cancer radiotherapy